Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Etcembly a Revolutionary Machine Learning Biotech Firm Agrees Deal to Develop New Cancer Treatments

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Etcembly, a revolutionary biotech company that uses machine learning to identify and predict the effectiveness of future immune therapies, has agreed a partnership with leading Norwegian firm Zelluna to engineer T-cell receptors (TCRs) from Zelluna’s pipeline against an undisclosed cancer target.

Etcembly notes the commercial agreement will involve Etcembly engineering Zelluna’s TCR candidates and Zelluna developing these further through comprehensive preclinical assessments and beyond into development.

The Oxford-based business will incorporate “hundreds of millions of data points” to rigorously test molecular adaptations within a quarter of the time it typically takes using traditional methods.

It is hoped the deal will help in the development of future treatments for a variety of cancers.

Etcembly CEO Dr Michelle Teng said the agreement could be a major turning point for discovering new immunotherapies for the disease.

“This partnership agreement with Zelluna represents a huge step forward for the research and development of new cancer treatments,” she said.

“We aim to drastically compress preclinical timelines and provide solid validation for clinical candidates by delivering evidence for TCR efficacy and safety.

“We very much look forward to working with Zelluna to help speed up pre-clinical research in the race to find new cancer treatments.”

The deal will involve Etcembly testing and optimising Zelluna TCR candidates over the next 12 months.

The Norwegian business hopes the move will help to develop optimised TCR-guided natural killer cell therapies for multiple solid cancers.

As one of the only companies in the world to incorporate machine learning into its molecular testing, Dr Teng added that Etcembly’s approach to combining machine learning with gene therapy could save the pharma industry “years of testing and millions of pounds”.

Dr Teng also believes the deal with Zelluna could help to accelerate the wider adoption of machine learning technologies across the sector.

“The benefits are too great to ignore,” she said. “The latest technologies, combined with the data points we now have available, makes it an invaluable tool to rapidly increase turnaround in the development of new therapies.

“As machine learning gathers momentum, it will no doubt become a staple for pharmaceutical companies in the future.

“Already, we are pushing the frontiers to explore the intersection between immunology and machine learning, which has the potential to transform the sector in the coming years.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine